Want to join the conversation?
$BMY's 1Q16 revenue grew 9% versus 1Q15 due to higher Opdivo, Eliquis and Daklinza product sales. US and Europe revenue rose in the quarter, mainly due to higher demand for Opdivo and Eliquis. Decrease in Rest of the World revenue was driven by lower demand due to increased competition for the Hepatitis C Franchise in Japan.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?